Scott Auerbach
Concepts (391)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 41 | 2026 | 736 | 7.660 |
Why?
| | Heart-Assist Devices | 22 | 2026 | 567 | 3.880 |
Why?
| | Heart Failure | 27 | 2026 | 2314 | 2.780 |
Why?
| | Graft Rejection | 13 | 2025 | 540 | 2.120 |
Why?
| | Graft Survival | 11 | 2025 | 526 | 2.000 |
Why?
| | Toxicity Tests | 7 | 2025 | 38 | 1.180 |
Why?
| | Gene Expression Profiling | 11 | 2025 | 1782 | 1.160 |
Why?
| | Heart Defects, Congenital | 12 | 2026 | 913 | 1.140 |
Why?
| | Muscular Dystrophy, Duchenne | 5 | 2025 | 91 | 1.120 |
Why?
| | Transcriptome | 12 | 2025 | 1044 | 1.110 |
Why?
| | Cardiomyopathies | 10 | 2025 | 337 | 1.080 |
Why?
| | Child | 59 | 2026 | 22537 | 1.080 |
Why?
| | Mutagens | 6 | 2025 | 26 | 1.000 |
Why?
| | Heart Diseases | 3 | 2023 | 349 | 1.000 |
Why?
| | Glomerular Filtration Rate | 3 | 2026 | 758 | 0.990 |
Why?
| | Liver | 9 | 2025 | 1884 | 0.980 |
Why?
| | Toxicogenetics | 5 | 2023 | 6 | 0.860 |
Why?
| | Carcinogens | 5 | 2025 | 122 | 0.820 |
Why?
| | Steroids | 2 | 2015 | 160 | 0.810 |
Why?
| | Myocarditis | 2 | 2023 | 102 | 0.780 |
Why?
| | Child, Preschool | 29 | 2026 | 11774 | 0.770 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2025 | 653 | 0.700 |
Why?
| | Immunosuppressive Agents | 5 | 2025 | 846 | 0.670 |
Why?
| | Kidney Transplantation | 3 | 2026 | 704 | 0.670 |
Why?
| | Adolescent | 39 | 2026 | 22281 | 0.660 |
Why?
| | Toxicology | 4 | 2025 | 49 | 0.660 |
Why?
| | Registries | 15 | 2025 | 2382 | 0.630 |
Why?
| | Environmental Pollutants | 4 | 2025 | 166 | 0.620 |
Why?
| | Humans | 99 | 2026 | 144261 | 0.610 |
Why?
| | Organ Transplantation | 4 | 2024 | 247 | 0.610 |
Why?
| | Liver Neoplasms, Experimental | 2 | 2018 | 26 | 0.590 |
Why?
| | Small Molecule Libraries | 2 | 2017 | 110 | 0.580 |
Why?
| | Retrospective Studies | 25 | 2026 | 17009 | 0.550 |
Why?
| | Infant | 23 | 2026 | 10022 | 0.550 |
Why?
| | Treatment Outcome | 20 | 2025 | 11643 | 0.530 |
Why?
| | Plant Preparations | 3 | 2025 | 37 | 0.530 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 597 | 0.520 |
Why?
| | Exome | 1 | 2018 | 227 | 0.510 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 390 | 0.510 |
Why?
| | Male | 49 | 2026 | 72035 | 0.500 |
Why?
| | Coronary Artery Disease | 2 | 2020 | 741 | 0.500 |
Why?
| | Prosthesis-Related Infections | 1 | 2017 | 99 | 0.490 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 529 | 0.480 |
Why?
| | Disease Management | 1 | 2020 | 643 | 0.480 |
Why?
| | Cardiomyopathy, Dilated | 4 | 2022 | 359 | 0.470 |
Why?
| | Risk Factors | 16 | 2026 | 10699 | 0.460 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 824 | 0.450 |
Why?
| | Extracorporeal Membrane Oxygenation | 4 | 2022 | 382 | 0.450 |
Why?
| | Follow-Up Studies | 10 | 2025 | 5389 | 0.440 |
Why?
| | Cardiology | 1 | 2017 | 353 | 0.420 |
Why?
| | Stroke | 1 | 2023 | 1254 | 0.420 |
Why?
| | Young Adult | 14 | 2024 | 13990 | 0.410 |
Why?
| | Benchmarking | 5 | 2024 | 188 | 0.400 |
Why?
| | Myocardium | 3 | 2022 | 939 | 0.400 |
Why?
| | High-Throughput Screening Assays | 5 | 2020 | 174 | 0.400 |
Why?
| | Female | 38 | 2026 | 77976 | 0.390 |
Why?
| | Sequence Analysis, RNA | 2 | 2014 | 442 | 0.380 |
Why?
| | Risk Assessment | 7 | 2025 | 3637 | 0.370 |
Why?
| | Histones | 1 | 2017 | 668 | 0.350 |
Why?
| | Biomarkers | 9 | 2025 | 4254 | 0.340 |
Why?
| | Postoperative Complications | 6 | 2025 | 2916 | 0.330 |
Why?
| | Echocardiography | 3 | 2022 | 647 | 0.330 |
Why?
| | DNA Damage | 5 | 2025 | 428 | 0.330 |
Why?
| | Delivery of Health Care | 1 | 2017 | 940 | 0.320 |
Why?
| | Gene Expression Regulation | 5 | 2025 | 2603 | 0.320 |
Why?
| | Dietary Supplements | 3 | 2019 | 575 | 0.320 |
Why?
| | Mutation | 2 | 2019 | 4085 | 0.320 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2010 | 109 | 0.310 |
Why?
| | Metabolomics | 4 | 2024 | 726 | 0.310 |
Why?
| | Waiting Lists | 4 | 2024 | 263 | 0.300 |
Why?
| | Computational Biology | 4 | 2025 | 680 | 0.300 |
Why?
| | Cimicifuga | 2 | 2019 | 2 | 0.300 |
Why?
| | Transforming Growth Factor alpha | 1 | 2009 | 56 | 0.300 |
Why?
| | Transplant Recipients | 4 | 2024 | 180 | 0.290 |
Why?
| | Mutagenicity Tests | 4 | 2025 | 14 | 0.280 |
Why?
| | Databases, Factual | 5 | 2024 | 1484 | 0.270 |
Why?
| | Everolimus | 2 | 2025 | 111 | 0.270 |
Why?
| | Mycophenolic Acid | 2 | 2025 | 120 | 0.270 |
Why?
| | Tacrolimus | 2 | 2025 | 196 | 0.260 |
Why?
| | Genomics | 4 | 2023 | 833 | 0.250 |
Why?
| | Infant, Newborn | 11 | 2025 | 6424 | 0.250 |
Why?
| | Computer Simulation | 4 | 2021 | 1025 | 0.250 |
Why?
| | Plant Extracts | 2 | 2018 | 187 | 0.240 |
Why?
| | Formaldehyde | 2 | 2018 | 66 | 0.240 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 479 | 0.240 |
Why?
| | Ventricular Function, Left | 3 | 2022 | 538 | 0.240 |
Why?
| | Rats | 10 | 2025 | 5592 | 0.240 |
Why?
| | Animals | 24 | 2025 | 38030 | 0.230 |
Why?
| | Survival Rate | 4 | 2025 | 2088 | 0.230 |
Why?
| | Incidence | 4 | 2025 | 2870 | 0.230 |
Why?
| | Interleukin-6 | 1 | 2009 | 780 | 0.220 |
Why?
| | Alkanesulfonic Acids | 1 | 2025 | 49 | 0.220 |
Why?
| | Stroke Volume | 4 | 2022 | 648 | 0.210 |
Why?
| | Time Factors | 6 | 2025 | 7155 | 0.210 |
Why?
| | Biotransformation | 1 | 2024 | 62 | 0.210 |
Why?
| | Aflatoxin B1 | 2 | 2014 | 2 | 0.210 |
Why?
| | Kidney | 2 | 2023 | 1495 | 0.210 |
Why?
| | Animal Testing Alternatives | 2 | 2021 | 3 | 0.210 |
Why?
| | DNA | 2 | 2019 | 1460 | 0.210 |
Why?
| | Automobile Driving | 1 | 2026 | 155 | 0.200 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1533 | 0.200 |
Why?
| | Adverse Outcome Pathways | 1 | 2023 | 3 | 0.200 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 1322 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2025 | 2026 | 0.190 |
Why?
| | Consensus | 2 | 2025 | 488 | 0.190 |
Why?
| | Vasoplegia | 1 | 2022 | 5 | 0.190 |
Why?
| | Fluorocarbons | 1 | 2025 | 143 | 0.190 |
Why?
| | Heart Injuries | 1 | 2023 | 41 | 0.190 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2024 | 130 | 0.190 |
Why?
| | Muscular Dystrophies | 1 | 2022 | 30 | 0.190 |
Why?
| | Hep G2 Cells | 2 | 2025 | 74 | 0.180 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 170 | 0.180 |
Why?
| | Rodentia | 1 | 2022 | 61 | 0.180 |
Why?
| | American Heart Association | 2 | 2021 | 348 | 0.180 |
Why?
| | Ginkgo biloba | 2 | 2018 | 10 | 0.180 |
Why?
| | Adult | 12 | 2024 | 40262 | 0.180 |
Why?
| | Organisation for Economic Co-Operation and Development | 1 | 2021 | 2 | 0.180 |
Why?
| | Structure-Activity Relationship | 3 | 2017 | 567 | 0.170 |
Why?
| | Hepatocytes | 2 | 2019 | 221 | 0.170 |
Why?
| | Databases, Chemical | 2 | 2019 | 9 | 0.170 |
Why?
| | Clinical Protocols | 1 | 2022 | 282 | 0.170 |
Why?
| | Pesticides | 1 | 2021 | 63 | 0.170 |
Why?
| | Coronary Vessels | 2 | 2021 | 251 | 0.160 |
Why?
| | Practice Patterns, Physicians' | 2 | 2021 | 1347 | 0.160 |
Why?
| | Echinacea | 1 | 2019 | 2 | 0.160 |
Why?
| | Age Factors | 4 | 2021 | 3313 | 0.160 |
Why?
| | Adjustment Disorders | 1 | 2019 | 5 | 0.160 |
Why?
| | Quantitative Structure-Activity Relationship | 2 | 2017 | 20 | 0.160 |
Why?
| | Arsenites | 1 | 2019 | 6 | 0.150 |
Why?
| | Spironolactone | 1 | 2019 | 39 | 0.150 |
Why?
| | Cohort Studies | 5 | 2024 | 5935 | 0.150 |
Why?
| | Stents | 1 | 2023 | 556 | 0.150 |
Why?
| | Logistic Models | 1 | 2024 | 2104 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 964 | 0.150 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2019 | 339 | 0.150 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 68 | 0.140 |
Why?
| | Ultrasonography, Interventional | 1 | 2020 | 160 | 0.140 |
Why?
| | United States | 9 | 2022 | 15876 | 0.140 |
Why?
| | Food Contamination | 1 | 2018 | 56 | 0.140 |
Why?
| | Liver Transplantation | 1 | 2026 | 822 | 0.140 |
Why?
| | Eugenol | 1 | 2018 | 4 | 0.140 |
Why?
| | Gene Amplification | 1 | 2019 | 120 | 0.140 |
Why?
| | Ultrasonography | 2 | 2020 | 768 | 0.140 |
Why?
| | Tissue Fixation | 1 | 2018 | 36 | 0.140 |
Why?
| | Fontan Procedure | 1 | 2021 | 191 | 0.140 |
Why?
| | Paraffin Embedding | 1 | 2018 | 32 | 0.140 |
Why?
| | Coronary Angiography | 1 | 2020 | 322 | 0.140 |
Why?
| | Prostate | 1 | 2019 | 158 | 0.140 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 253 | 0.130 |
Why?
| | DNA, Neoplasm | 1 | 2018 | 163 | 0.130 |
Why?
| | HEK293 Cells | 2 | 2018 | 744 | 0.130 |
Why?
| | Mice, Inbred Strains | 1 | 2018 | 397 | 0.130 |
Why?
| | Isoantibodies | 1 | 2017 | 57 | 0.130 |
Why?
| | Cryopreservation | 1 | 2018 | 110 | 0.130 |
Why?
| | Cell Culture Techniques | 2 | 2017 | 375 | 0.130 |
Why?
| | Global Health | 1 | 2020 | 394 | 0.130 |
Why?
| | Uniparental Disomy | 1 | 2017 | 9 | 0.130 |
Why?
| | Patient Selection | 1 | 2021 | 719 | 0.130 |
Why?
| | Anesthesia, Dental | 1 | 2017 | 22 | 0.130 |
Why?
| | Donor Selection | 1 | 2017 | 79 | 0.130 |
Why?
| | Research Design | 2 | 2023 | 1129 | 0.130 |
Why?
| | Epigenomics | 1 | 2017 | 114 | 0.130 |
Why?
| | Gene Expression | 2 | 2019 | 1487 | 0.130 |
Why?
| | Muscular Diseases | 1 | 2017 | 108 | 0.130 |
Why?
| | Tooth Extraction | 1 | 2017 | 28 | 0.130 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2926 | 0.130 |
Why?
| | Bundle-Branch Block | 1 | 2017 | 36 | 0.130 |
Why?
| | Arsenic | 1 | 2017 | 66 | 0.130 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 131 | 0.120 |
Why?
| | Artificial Intelligence | 1 | 2021 | 365 | 0.120 |
Why?
| | Depressive Disorder | 1 | 2019 | 374 | 0.120 |
Why?
| | HLA Antigens | 1 | 2017 | 225 | 0.120 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3403 | 0.120 |
Why?
| | DNA Repair | 2 | 2019 | 255 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1487 | 0.120 |
Why?
| | Models, Chemical | 1 | 2017 | 268 | 0.120 |
Why?
| | Systems Biology | 1 | 2016 | 72 | 0.120 |
Why?
| | Trisomy | 1 | 2017 | 78 | 0.120 |
Why?
| | Anesthesia, General | 1 | 2017 | 118 | 0.120 |
Why?
| | Cluster Analysis | 1 | 2017 | 519 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2018 | 758 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 279 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2019 | 582 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2020 | 533 | 0.110 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2017 | 139 | 0.110 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 402 | 0.110 |
Why?
| | Gene-Environment Interaction | 2 | 2017 | 180 | 0.110 |
Why?
| | Neuromuscular Diseases | 1 | 2017 | 145 | 0.110 |
Why?
| | Pharmaceutical Preparations | 1 | 2017 | 169 | 0.110 |
Why?
| | Heme Oxygenase-1 | 1 | 2015 | 74 | 0.110 |
Why?
| | Equipment Failure | 1 | 2015 | 115 | 0.110 |
Why?
| | Aromatase Inhibitors | 1 | 2015 | 75 | 0.110 |
Why?
| | Biomarkers, Pharmacological | 1 | 2014 | 26 | 0.110 |
Why?
| | Receptors, Estrogen | 1 | 2018 | 457 | 0.110 |
Why?
| | Perioperative Care | 1 | 2017 | 230 | 0.110 |
Why?
| | RNA, Messenger | 3 | 2024 | 2829 | 0.110 |
Why?
| | Freezing | 1 | 2014 | 85 | 0.110 |
Why?
| | Vaccination | 4 | 2024 | 1422 | 0.110 |
Why?
| | Rats, Inbred F344 | 1 | 2014 | 268 | 0.100 |
Why?
| | Cell Survival | 1 | 2017 | 1098 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1705 | 0.100 |
Why?
| | Crohn Disease | 1 | 2017 | 260 | 0.100 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 555 | 0.100 |
Why?
| | Cell Membrane | 1 | 2017 | 706 | 0.100 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 25 | 0.100 |
Why?
| | Dexmedetomidine | 1 | 2013 | 44 | 0.100 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 778 | 0.100 |
Why?
| | Propensity Score | 1 | 2015 | 367 | 0.100 |
Why?
| | Proteome | 1 | 2017 | 514 | 0.090 |
Why?
| | Hemodynamics | 2 | 2018 | 1119 | 0.090 |
Why?
| | Epithelial Cells | 1 | 2019 | 1125 | 0.090 |
Why?
| | Disease Progression | 1 | 2020 | 2840 | 0.090 |
Why?
| | Genetic Diseases, Inborn | 1 | 2012 | 44 | 0.090 |
Why?
| | Quality Improvement | 1 | 2021 | 1285 | 0.090 |
Why?
| | Heart | 2 | 2022 | 633 | 0.090 |
Why?
| | Anxiety | 1 | 2019 | 1104 | 0.090 |
Why?
| | Models, Genetic | 1 | 2014 | 535 | 0.090 |
Why?
| | Respiratory Insufficiency | 1 | 2015 | 326 | 0.090 |
Why?
| | Hospitalization | 1 | 2022 | 2424 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2025 | 1044 | 0.090 |
Why?
| | Mental Disorders | 1 | 2020 | 1138 | 0.090 |
Why?
| | Kidney Diseases | 1 | 2015 | 425 | 0.080 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 878 | 0.080 |
Why?
| | Recovery of Function | 1 | 2015 | 706 | 0.080 |
Why?
| | Antibody Formation | 2 | 2022 | 294 | 0.080 |
Why?
| | Oxidative Stress | 1 | 2017 | 1339 | 0.080 |
Why?
| | Propanolamines | 1 | 2010 | 40 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 725 | 0.080 |
Why?
| | Carbazoles | 1 | 2010 | 56 | 0.080 |
Why?
| | Pediatrics | 1 | 2018 | 1112 | 0.080 |
Why?
| | Prognosis | 3 | 2018 | 4278 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2017 | 2494 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 2111 | 0.080 |
Why?
| | Signal Transduction | 3 | 2018 | 5221 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2014 | 1983 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 427 | 0.070 |
Why?
| | Carcinogenicity Tests | 2 | 2022 | 10 | 0.070 |
Why?
| | Prospective Studies | 5 | 2026 | 7970 | 0.070 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 527 | 0.070 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6021 | 0.070 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2010 | 250 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2024 | 672 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 700 | 0.070 |
Why?
| | Survival Analysis | 1 | 2011 | 1382 | 0.070 |
Why?
| | Transplantation, Homologous | 1 | 2009 | 415 | 0.070 |
Why?
| | Biological Assay | 2 | 2018 | 127 | 0.070 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2007 | 15 | 0.070 |
Why?
| | RNA | 1 | 2014 | 939 | 0.070 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 78 | 0.060 |
Why?
| | Genotype | 2 | 2009 | 1833 | 0.060 |
Why?
| | Receptors, Aryl Hydrocarbon | 2 | 2019 | 60 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 2 | 2024 | 2525 | 0.060 |
Why?
| | Neoplasms | 1 | 2022 | 2870 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1054 | 0.060 |
Why?
| | Hemofiltration | 1 | 2006 | 24 | 0.060 |
Why?
| | Biopsy | 1 | 2009 | 1075 | 0.060 |
Why?
| | Lymphoproliferative Disorders | 1 | 2025 | 57 | 0.060 |
Why?
| | Exons | 2 | 2019 | 358 | 0.060 |
Why?
| | ROC Curve | 2 | 2019 | 612 | 0.060 |
Why?
| | Caprylates | 1 | 2025 | 27 | 0.060 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 612 | 0.050 |
Why?
| | Aged | 2 | 2023 | 25850 | 0.050 |
Why?
| | Equipment Design | 1 | 2026 | 530 | 0.050 |
Why?
| | Catheterization, Peripheral | 1 | 2006 | 117 | 0.050 |
Why?
| | Catheterization, Central Venous | 1 | 2006 | 122 | 0.050 |
Why?
| | Gene Regulatory Networks | 2 | 2019 | 318 | 0.050 |
Why?
| | Middle Aged | 3 | 2023 | 35762 | 0.050 |
Why?
| | Cytomegalovirus Infections | 1 | 2025 | 206 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2018 | 2516 | 0.050 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2023 | 40 | 0.050 |
Why?
| | Workflow | 1 | 2025 | 184 | 0.050 |
Why?
| | Cell Line | 2 | 2019 | 2879 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 187 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 549 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 138 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1980 | 0.040 |
Why?
| | Antibodies | 1 | 2024 | 401 | 0.040 |
Why?
| | Bias | 1 | 2022 | 201 | 0.040 |
Why?
| | Replantation | 1 | 2021 | 32 | 0.040 |
Why?
| | Mice | 3 | 2025 | 18329 | 0.040 |
Why?
| | Prosthesis Design | 1 | 2023 | 354 | 0.040 |
Why?
| | Insurance Coverage | 1 | 2022 | 238 | 0.040 |
Why?
| | Mammals | 1 | 2022 | 291 | 0.040 |
Why?
| | Data Accuracy | 1 | 2021 | 65 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 221 | 0.040 |
Why?
| | Social Class | 1 | 2022 | 268 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 229 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2019 | 4146 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2022 | 283 | 0.040 |
Why?
| | PPAR alpha | 1 | 2019 | 54 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5813 | 0.040 |
Why?
| | Carcinogens, Environmental | 1 | 2019 | 14 | 0.040 |
Why?
| | Documentation | 1 | 2021 | 197 | 0.040 |
Why?
| | Cricetulus | 1 | 2019 | 118 | 0.040 |
Why?
| | CHO Cells | 1 | 2019 | 171 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 173 | 0.040 |
Why?
| | Chickens | 1 | 2019 | 191 | 0.040 |
Why?
| | Prevalence | 1 | 2026 | 2815 | 0.040 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2019 | 56 | 0.040 |
Why?
| | Micronucleus Tests | 1 | 2018 | 6 | 0.040 |
Why?
| | Therapeutic Equivalency | 1 | 2018 | 31 | 0.030 |
Why?
| | Anemia, Megaloblastic | 1 | 2018 | 9 | 0.030 |
Why?
| | Micronuclei, Chromosome-Defective | 1 | 2018 | 8 | 0.030 |
Why?
| | Hyperplasia | 1 | 2018 | 174 | 0.030 |
Why?
| | Myocardial Contraction | 1 | 2019 | 298 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2018 | 40 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 209 | 0.030 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2019 | 214 | 0.030 |
Why?
| | Muscular Dystrophy, Emery-Dreifuss | 1 | 2017 | 3 | 0.030 |
Why?
| | Phytotherapy | 1 | 2018 | 74 | 0.030 |
Why?
| | Myopathies, Structural, Congenital | 1 | 2017 | 5 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2021 | 744 | 0.030 |
Why?
| | Muscular Dystrophies, Limb-Girdle | 1 | 2017 | 6 | 0.030 |
Why?
| | Activation, Metabolic | 1 | 2017 | 5 | 0.030 |
Why?
| | Barth Syndrome | 1 | 2017 | 9 | 0.030 |
Why?
| | International Cooperation | 1 | 2018 | 197 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2019 | 242 | 0.030 |
Why?
| | Myotonic Dystrophy | 1 | 2017 | 10 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2017 | 78 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2018 | 194 | 0.030 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2017 | 36 | 0.030 |
Why?
| | Brazil | 1 | 2017 | 179 | 0.030 |
Why?
| | Infliximab | 1 | 2017 | 108 | 0.030 |
Why?
| | Hazardous Substances | 1 | 2016 | 15 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 66 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2017 | 148 | 0.030 |
Why?
| | Sample Size | 1 | 2017 | 123 | 0.030 |
Why?
| | Death | 1 | 2017 | 130 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2018 | 248 | 0.030 |
Why?
| | Folic Acid | 1 | 2018 | 199 | 0.030 |
Why?
| | Mosaicism | 1 | 2017 | 73 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 336 | 0.030 |
Why?
| | DNA Methylation | 1 | 2021 | 681 | 0.030 |
Why?
| | Friedreich Ataxia | 1 | 2017 | 78 | 0.030 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2016 | 60 | 0.030 |
Why?
| | Pulsatile Flow | 1 | 2016 | 55 | 0.030 |
Why?
| | Echocardiography, Transesophageal | 1 | 2017 | 133 | 0.030 |
Why?
| | Canada | 1 | 2017 | 428 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 371 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2017 | 538 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1646 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2022 | 1313 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2015 | 135 | 0.030 |
Why?
| | Catheters | 1 | 2015 | 75 | 0.030 |
Why?
| | Colonoscopy | 1 | 2017 | 260 | 0.030 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 95 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2014 | 17 | 0.030 |
Why?
| | Kidney Tubules, Proximal | 1 | 2015 | 130 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2019 | 2025 | 0.030 |
Why?
| | Drugs, Investigational | 1 | 2014 | 31 | 0.030 |
Why?
| | Tissue Donors | 1 | 2017 | 424 | 0.030 |
Why?
| | Gene Library | 1 | 2014 | 126 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 341 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2017 | 1172 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2021 | 3592 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 312 | 0.030 |
Why?
| | Area Under Curve | 1 | 2014 | 329 | 0.030 |
Why?
| | Glucuronosyltransferase | 1 | 2013 | 18 | 0.020 |
Why?
| | Electrocardiography | 1 | 2017 | 660 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1255 | 0.020 |
Why?
| | E2F1 Transcription Factor | 1 | 2013 | 68 | 0.020 |
Why?
| | Radiation Effects | 1 | 2012 | 7 | 0.020 |
Why?
| | Genetic Variation | 1 | 2018 | 982 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2013 | 197 | 0.020 |
Why?
| | Alternative Splicing | 1 | 2014 | 247 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1028 | 0.020 |
Why?
| | Erythrocytes | 1 | 2018 | 757 | 0.020 |
Why?
| | Models, Molecular | 1 | 2017 | 1618 | 0.020 |
Why?
| | Estradiol | 1 | 2015 | 533 | 0.020 |
Why?
| | Germ-Line Mutation | 1 | 2012 | 172 | 0.020 |
Why?
| | Tobacco Products | 1 | 2012 | 84 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2013 | 166 | 0.020 |
Why?
| | Testosterone | 1 | 2015 | 419 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3539 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2917 | 0.020 |
Why?
| | Heart Ventricles | 1 | 2015 | 756 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 3166 | 0.020 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2013 | 370 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1182 | 0.020 |
Why?
| | Lung | 1 | 2021 | 4108 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2007 | 121 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1455 | 0.020 |
Why?
| | Echocardiography, Doppler | 1 | 2007 | 115 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 573 | 0.020 |
Why?
| | DNA Primers | 1 | 2007 | 511 | 0.020 |
Why?
| | Gene Frequency | 1 | 2007 | 481 | 0.020 |
Why?
| | Subclavian Vein | 1 | 2006 | 15 | 0.010 |
Why?
| | Pregnancy | 1 | 2017 | 7180 | 0.010 |
Why?
| | Alleles | 1 | 2007 | 878 | 0.010 |
Why?
| | Base Sequence | 1 | 2007 | 2187 | 0.010 |
Why?
| | Phenotype | 1 | 2007 | 3157 | 0.010 |
Why?
|
|
Auerbach's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|